PDCD1 and head and neck neoplasm: Many of the tumor types with high median TIS values, in particular advanced/metastatic renal clear cell carcinoma [21], melanoma [22], lung tumors [23], and head and neck tumors [24], have shown clinical sensitivity to anti-PD-1 blockade (Additional file 2: Figure S1).